Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
It has been well established that hyperthyroidism leads to diminished bone mineral density (BMD), and that a previous history of hyperthyroidism remains a risk factor for fractures. However, little is known about how to manage the reduction in BMD caused by hyperthyroidism. The purpose of this study was to evaluate the efficacy of risedronate for the treatment of osteoporosis/osteopenia in patients with Graves' disease (GD). Of 34 Japanese male patients with newly diagnosed GD, 27 with osteoporosis/osteopenia were included in this study. They were randomly divided into two groups by therapeutic regimen. Group A consisted of 14 patients treated with an antithyroid drug and risedronate. Group B consisted of 13 patients treated with the same antithyroid drug only. We used dual-energy X-ray absorptiometry to measure BMD at the lumber spine, femoral neck, and distal radius at baseline, and at 6 and 12 months after the trial. Bone-specific alkaline phosphatase and urinary N-terminal telopeptide of type I collagen normalized by creatinine were significantly more reduced in group A than in group B after both 6 and 12 months. The percentage increases in BMD at the lumbar spine and distal radius were significantly greater in group A than in group B. These beneficial effects of risedronate for patients with osteoporosis/osteopenia caused by GD may lead to a reduced risk of future fractures. We thus conclude that risedronate should be considered for the treatment of decreased bone mass associated with GD.
Majima
Takafumi
T
Department of Endocrinology and Metabolism, Rakuwakai Otowa Hospital, Kyoto, Japan.
Komatsu
Yasato
Y
Doi
Kentaro
K
Takagi
Chieko
C
Shigemoto
Michika
M
Fukao
Atsushi
A
Morimoto
Takeshi
T
Corners
Jerry
J
Nakao
Kazuwa
K
D000328:Adult; D000469:Alkaline Phosphatase / Q000378:metabolism; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D024042:Collagen Type I / Q000737:chemistry; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy; D007564:Japan; D008297:Male; D008875:Middle Aged; D015233:Models, Statistical; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy*; D010455:Peptides / Q000737:chemistry; D000068296:Risedronic Acid; D013963:Thyroid Hormones / Q000378:metabolism; D013997:Time Factors; D014965:X-Rays
D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010455:Peptides; D013963:Thyroid Hormones; C052929:collagen type I trimeric cross-linked peptide; D000469:Alkaline Phosphatase; D000068296:Risedronic Acid; D012968:Etidronic Acid